– Phase 1 data from the study expected to be available by December 2018 Aurigene, a biotechnology company focused on discovering and developing drugs for oncology and inflammatory disorders,
The Phase 2 trial is the result of the initial safety data and preliminary evidence of clinical benefit observed in the trial. Aurigene Discovery Technologies Limited, a wholly owned subsidiary
